Investigational drug · Phase 3
Pemvidutide
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
8
Any phase or sponsor naming "Pemvidutide"
First trial start
2023
Jul 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pemvidutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alcohol-associated Liver Disease
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Alcohol Use Disorder (AUD)
- Non-Alcoholic Steatohepatitis (NASH)
Approved drugs for the same conditions: Alcohol dependence · MASH (fatty liver disease) · Psychiatry · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Pemvidutide" as an intervention, largest first.
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHPivotal-lookingRecruiting
Altimmune, Inc.Industry
NCT07795164 · 1,800 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 2028
Drug: Pemvidutide · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Sites: Dothan, Alabama; Chandler, Arizona; Tucson, Arizona · 62 sites in all
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
Altimmune, Inc.Industry
NCT05989711 · 212 participants · Start Jul 27, 2023 · Primary completion Nov 25, 2025
Drug: Pemvidutide; Placebo · For: Non-Alcoholic Steatohepatitis (NASH)
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 40 sites in all
- RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)Pivotal-lookingActive, not recruiting
Altimmune, Inc.Industry
NCT07009860 · 121 participants · Start Jun 16, 2025 · Primary completion Sep 30, 2027
Drug: Pemvidutide · For: Alcohol-associated Liver Disease
Sites: Peoria, Arizona; Tucson, Arizona; North Little Rock, Arkansas · 37 sites in all
- RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightPivotal-lookingCompleted
Altimmune, Inc.Industry
NCT06987513 · 100 participants · Start May 15, 2025 · Primary completion Jul 30, 2026
Drug: Pemvidutide · For: Alcohol Use Disorder (AUD)
Sites: Los Angeles, California; Aurora, Colorado; New Haven, Connecticut · 12 sites in all
- ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityPivotal-lookingCompleted
Altimmune, Inc.Industry
NCT04561245 · 100 participants · Start Nov 10, 2020 · Primary completion Oct 29, 2021
Drug: ALT-801 · For: Obesity; Nonalcoholic Steatohepatitis
Sites: Herston, Australia
Altimmune, Inc.Industry
NCT05006885 · 95 participants · Start Sep 30, 2021 · Primary completion Aug 17, 2022
Drug: ALT-801 · For: Non-Alcoholic Fatty Liver Disease
Sites: Scottsdale, Arizona; Tucson, Arizona; Montclair, California · 15 sites in all
- Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)Completed
Altimmune, Inc.Industry
NCT05292911 · 64 participants · Start Mar 9, 2022 · Primary completion Oct 31, 2022
Drug: ALT-801 · For: Non-Alcoholic Fatty Liver Disease
Sites: Montclair, California; Sacramento, California; Miami Lakes, Florida · 13 sites in all
Altimmune, Inc.Industry
NCT04972396 · 40 participants · Start Sep 15, 2021 · Primary completion May 15, 2022
Drug: Pemvidutide; Metformin and 4 more · For: NASH - Nonalcoholic Steatohepatitis
Sites: Adelaide, Australia; Brisbane, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.
Noureddin M, Alkhouri N, Loomba R, et al. · Lancet Gastroenterol Hepatol 2026
- GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.
Polepalli KV, Roshni P, Moka S, et al. · Dig Dis 2026
- From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism.
Saldívar-Cerón HI, Maldonado-Trejo D, Chavez-Castañeda Q, et al. · Int J Mol Sci 2026
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Santos Solis R, Baeza-Zapata AA, Negrete-Najar JP · Cureus 2026
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.
Rajab I, Emara A, Rakab MS, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.
Patil S, Jha N, Jha MK · Addict Behav Rep 2026
Also in development for Alcohol-associated Liver Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.